AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04844905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.
Study NCT04844905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
Study NCT04844905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
Study NCT05631522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body
Study NCT06461247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals
Description: Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy ketogenic breakfast. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
Study NCT06461247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: Participants will be provided with liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
Study NCT05353972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered
Study NCT06483243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
Description: At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
Study NCT05884424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARO Therapy Robot
Description: Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~1. Welcome and presentation.~2. Main activity with PARO.~3. PARO cleaning.~4. End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2).
Study NCT05583643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin loaded into nano particles in-situ gel adjunctive to scaling and debridement
Study NCT05583643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin loaded into in-situ gel adjunctive to scaling and debridement
Study NCT05583643 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scaling and debridement only
Description: Scaling and debridement only
Study NCT05578105 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention, only observation
Study NCT05021458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's mobilization
Description: Ten patients will be treated with Gong's mobilization.
Study NCT05021458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAG
Description: : Ten patients will be treated with SNAGs
Study NCT04734847 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)
Description: Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
Study NCT05011890 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Moovcare® use
Description: Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
Study NCT06431685 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Low Dose Radiotherapy
Description: Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: Group 1: 4 Gy/2f of one cycle; Group 2: 4 Gy/2f of two cycles (Q3w); Group 3: 4 Gy/2f of three cycles (Q3w). WB-LDRT will be administered in a 4 Gy of 2 fractions over two days, starting from Day 1 in the first cycle (a daily dose of 2 Gy, 4 Gy/2f for one cycle, once per three weeks, at minmum in one cycle and maximum in four cycles in total).
Study NCT06431685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 30 mg, intrathecal injection, once per three weeks, 4 cycles in total
Study NCT06431685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor (Sintilimab, dose as recommended in the instruction manual), intravenous infusion, once per three weeks, 4 cycles in total
Study NCT06431685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
Study NCT06204406 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: This is a prospective observational study with observation only and no intervention
Study NCT06254508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online program that includes exercise guided by the FITT-VP principle and dietary advice
Description: 1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance.
Study NCT06254508 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in-clinic nutrition and exercise advice and self-control
Description: Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
Study NCT05615805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSDI questionnaire
Description: Ocular Surface Disease Index
Study NCT05615805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPEEDII questionnaire
Description: Standardized Patient Evaluation of Eye Dryness II questionnaire
Study NCT06278727 — intervention group
Intervention type: DRUG
Intervention: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor
Description: Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.
Study NCT06278727 — intervention group
Intervention type: OTHER
Intervention: The development of the prediction model
Description: The prediction model of FMR regression would be developed to recognize patients whose FMR would regress due to GDMT, and consequently help determine the treatment.
Study NCT05848882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastodontic Device
Description: Removable device that embraces two dental archs
Study NCT06509971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab.
Study NCT05822362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.
Study NCT05822362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm.
Study NCT05473689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
Study NCT05473689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
Study NCT05285722 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy form for dental anxiety
Description: Message to Dentist form
Study NCT06197412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao
Description: On the basis of the optimal clinical treatment scheme, Yunnan Baiyao powder or ointment was used to treat the wound for 2 weeks
Study NCT05523141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC10
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo for 5.5 days, in an double-blind manner~Part 2:~Two single oral doses of ASC10 will be administered to participants, in an open-label manner
Study NCT05523141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1:~Participants will be randomized to receive twice daily dosing either ASC10 or Placebo, in an double-blind manner
Study NCT05496608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: a blood sample is obtained from the patient, and centrifuged to prepare a leukocyte platelet rich fibrin harvest that is applied within the derided lesion.
Study NCT05496608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD
Description: Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
Study NCT05496608 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OFD
Description: Full thickness flap elevation to gain access to the infrabony lesion for debridement followed by flap closure.
Study NCT05496608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CM
Description: Xenogeneic collagen membranes that are used as barrier membranes in guided tissue regeneration of periodontal defects
Study NCT05900817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antivet
Description: A material used for micro abrasion of teeth
Study NCT05900817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oplsture
Description: A material used for micro abrasion of teeth
Study NCT05237284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443820
Description: Tablet oral
Study NCT05237284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT05738122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60-Day self-guided Emotion Regulation Journal
Description: A 60-day self guided journal with activities designed to be completed daily to improve an individual's emotion regulation abilities and habits
Study NCT05493813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive function and delirium evaluation
Description: Cognitive functions (including delirium) will be assessed pre-procedure (baseline) and emergency department (before EVT), on day 1 and 7 and 3 months after EVT procedure
Study NCT05493813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurological functional assessment
Description: National Institute of Health Stroke Scale (NIHSS) and modified Rankin scale (mRS) will be assessed before (baseline but after stroke) and after EVT on days 1 and 7 after procedure up to 3 months follow-up.
Study NCT06384456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical TRanexamic Acid
Description: 10mL of 100mg/mL TXA will be administered into the surgical wound prior closure.
Study NCT06384456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mL of 100mg/mL normal saline will be administered into the surgical wound prior closure.
Study NCT05577910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vectored thermal pulsation (VTP) therapy
Description: VTP purchased from TearScience®️ is an automated thermal pulsation system that is designed to heat and simultaneously evacuate the meibomian gland contents. It is performed by the unmasked treating investigators as described by the equipment manufacturer. In brief, one to two drops of topical anesthesia are applied prior to the bilateral application of the activators. The inner portion of the activator applies a constant temperature of 42.5°C to the tarsal conjunctiva of upper and lower eyelids. Simultaneously, the outer portion of the activator applies directional, pulsatile pressure to the external eyelid surfaces (maximum 6 psi) for the 12-minute treatment cycle. Participants will receive one session of VTP treatment only (month 0).
Study NCT05577910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light with meibomian gland expression (IPL+MGX) therapy
Description: IPL is delivered using the proprietary dry eye mode setting of the Lumenis®️ M22TM system per the Toyos protocol. Pulse intensity (11-14 J/cm2) is inversely related to the Fitzpatrick skin phototype of each participant and will be used for the same patient throughout the study. IPL will be delivered to four overlapping zones inferior to each eye and a fifth pulse applied temporally adjacent to the lateral canthus four times. Both eyelids are closed and sealed with IPL-Aid disposable eye shields. MGX is immediately performed on both upper and lower eyelids of each eye and pain will be minimized by topical anesthetic. Participants will receive four-session IPL and MGX treatment (month 0, 1, 2 ,3).
Study NCT05577910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eyelid Warm Compress Therapy (EW)
Description: EW using warm wet towel to each eye is performed twice daily for 10 mins. A treatment diary will be given for patients randomized to EW for daily recording which will be reviewed and recorded by the unmasked study coordinator at each study visit.
Study NCT05577910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical eye drops (Hypromellose, 3mg/ml)
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
Study NCT05577910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical eye drops (Hypromellose, 3mg/ml)
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
Study NCT06293105 — intervention group
Intervention type: OTHER
Intervention: Qualitative interview, participant observation
Description: Qualitative in-depth interviews to explore experiences of and perspectives on stigma and discrimination, linked to being present in settings where there is participant observation
Study NCT05640284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nuclear Factor-Kappa B Ligand (RANKL) analysis
Description: samples of peri-implant groove fluid will be taken with paper strips and RANKL assessment will be made
Study NCT05640284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Osteoprotegerin (OPG) analysis
Description: samples of peri-implant groove fluid will be taken with paper strips and OPG assessment will be made
Study NCT05640284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Necrosis Factor Alpha (TNF-α) analysis
Description: samples of peri-implant groove fluid will be taken with paper strips and TNF-α assessment will be made
Study NCT05640284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MicroRNA-223 analysis
Description: samples of peri-implant groove fluid will be taken with paper strips and MicroRNA-223 assessment will be made
Study NCT05640284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microrna-27a analysis
Description: samples of peri-implant groove fluid will be taken with paper strips and Microrna-27a assessment will be made
Study NCT04493151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem, Cilastatin and Relebactam
Description: After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
Study NCT05876793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: The fixed dose of propofol in this study was 0.5mg/kg, with an injection time of 30 seconds. Subsequently, remimazolam was administered at an initial dose of 0.1mg/kg. After 1 minute of administration, sedation was evaluated using MOAA/S. When the MOAA/S score was ≤ 1, endoscopic examination could begin. If the patient did not show physical activity or coughing, sedation was considered successful, and the next patient's medication dose was reduced by 0.02mg/kg; On the contrary, if sedation fails, the next patient will receive an additional 0.02mg/kg of medication.Successful sedation results in a positive reaction, while failure results in a negative reaction. This study ends when 7 positive and negative reactions intersect
Study NCT05919095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrilizumab plus GEMOX
Description: PD-1 antibody，200mg，D1，intravenous infusion, the administration time is 60 (+15) minutes.~GEMOX chemotherapy : gemcitabine 1000mg/m2,D1，D8；oxaliplatin 100mg/m2,D1intravenous infusion.Three weeks is a course of treatment.
Study NCT06646510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercises
Description: strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand
Study NCT06646510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional exercises
Description: strengthening exercise for the shoulder muscles( shoulder extensors, shoulder retractors from prone position and shoulder external rotation exercise for 3 sets 10 repetition , weight bearing exercise on the hand from quadruped position and sitting position and strengthening exercise on the intrinsic muscles of the hand